Membranoproliferative GN I

Injury	Disease	Nutrition	Poison

Symptoms	Surgery	Test	Special Topic

Kidney anatomy

Membranoproliferative GN I

Alternative Names:

Mesangiocapillary glomerulonephritis (type I); Membranoproliferative glomerulonephritis (type I); Lobular GN; Glomerulonephritis - membranoproliferative (type I); MPGN type I
Treatment:

text continues below

Treatment may vary according to the symptoms. Treatment goals include reduction of symptoms, prevention of complications, and slowed progression of the disorder. Steroids and cytotoxic agents have been used and may benefit certain individuals. Dipyridamole has also been used in some individuals.

Dietary adjustments may include restrictions on sodium (see sodium in diet ), fluids, protein, or other restrictions as appropriate to control high blood pressure, swelling, and accumulation of waste products in the bloodstream.

Antihypertensive medications are critical to help control blood pressure. Diuretics or other medications may be appropriate to control swelling orother symptoms.

Dialysis or kidney transplant may eventually be required to manage kidney failure. Combination therapy with aspirin and dipyridamole may slow progression to renal failure with MPGN 1. This treatment is of unproven value.

Expectations (prognosis):

The disorder progresses slowly to chronic renal failure. Fifty percent of cases will develop chronic renal failure within 10 years.

Complications:

Calling your health care provider:

Call for an appointment with your health care provider if symptoms indicate MPGN I may be present.

Call for an appointment with your health care provider if symptoms worsen or persist, or if new symptoms develop, including decreased urine output.